MPMichał Petelenz

Michał Petelenz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michał Petelenz has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Verification of the authenticity of drugs by means of NMR relaxometry—Viagra ® as an example

    by S. Wilczyńki, M. Petelenz, M. Florek-Wojciechowska, S. Kulesza, Sz. Brym, B. Błońska-Fajfrowska, D. Kruk


  • Taste and appetite disorders of chronic hepatitis C patients

    by Joanna Musialik, Wanda Suchecka, Ewa Klimacka-Nawrot, Michał Petelenz, Magdalena Hartman, Barbara Błońska-Fajfrowska

    Objective Decreased appetite is one of the main factors that influences quality of life of patients with chronic liver diseases. The reason for appetite disorders remains unclear but taste perturbations are one of the postulated causes. The potential role of taste alterations and, connected to these, appetite disorders in chronic hepatitis C (CHC) patients are poorly investigated. The aim of this study was to evaluate potential taste alterations (dysgeusia) including all five tastes (sweet, salty, bitter, sour and umami) in CHC patients. Methods Forty CHC patients (16 men and 24 women) infected with genotype 1 hepatitis C virus participated in this study. All the patients had a compensated liver disease and were being treated with any agents. One hundred and ten healthy volunteers were matched to the patients by age and sex. The study included gustatory tests (taste recognition threshold, taste intensity with hedonic perception) and analysis of the pleasure derived from eating. Results In CHC patients, the recognition threshold of umami taste was increased (PPPP<0.05) was also observed. Some differences in case of the patients with more advanced disease were also found. Conclusion Alterations in taste, especially umami and sweet taste disorders, may alter real food perception and lead to a reduction in food intake in some CHC patients.


    • 1 January 2010
      • Vol. 63  (4) , 289-99

    Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.

    by Ewa Klimacka-Nawrot, Joanna Musialik, Wanda Suchecka, Michał Petelenz, Magdalena Hartman, Paweł Lichtański, Barbara Błońska-Fajfrowska

    The effectiveness of current standard therapy of chronic hepatitis C with pegylated interferon-alpha and ribavirin is unsatisfactory and associated with a variety of side effects. In addition to common side effects, appetite disorders and weight loss are universal problems that lead to decreased quality of life. The causes of appetite disorders are not known. The aim of the present study was to evaluate the influence of pegylated interferon-alpha 2b and ribavirin therapy on taste sensitivity, hedonic perception of taste sensations, and food preferences. Nineteen chronic hepatitis C patients infected with genotype 1 HCV participated in the study. All patients received combined therapy with pegylated interferon-alpha 2b and ribavirin in adequate doses. The study included gustatory tests (taste recognition threshold and taste intensity with hedonic perception) using a gustometric method and an evaluation of the pleasure derived from eating. All examinations were performed before therapy and during the thirteenth week of therapy. After 12 weeks of therapy, patient sensitivity to salty and sweet was significantly decreased (p < 0.05), and bitter was described as being more unpleasant than before the therapy (p < 0.05). Also, the therapy decreased appetite without significant changes in patients' food preferences. We found multidirectional taste disturbances during treatment with pegylated interferon and ribavirin. The results may be useful in determining the role of taste in the development of appetite disorders in chronic hepatitis C patients treated with pegylated interferon and ribavirin.


    • 1 January 2010
      • Vol. 61  (3) , 154-60

    Association between liver steatosis and angiogenesis in chronic hepatitis C.

    by Michał Kukla, Andrzej Gabriel, Daniel Sabat, Łukasz Liszka, Mariusz Wilk, Michał Petelenz, Joanna Musialik, Iwona Dzindziora-Frelich

    The relationship between steatosis and angiogenesis in chronic hepatitis C (CHC) is unclear. The aim was to explain whether liver steatosis presence and its extent are associated with the number of new-formed blood vessels in lobules and portal tracts in CHC. 72 CHC patients infected with viral genotype 1b, 35 of whom had steatosis were evaluated. Monoclonal antibody anti-CD34 was used to identify new-formed blood vessels. Patients with steatosis had a significantly more advanced stage of fibrosis (p = 0.002) and higher inflammatory activity grade (p = 0.062). CD34 expression in portal tracts (CD34pt), lobules and fibrous septa (CD34lfs) and total (CD34) were significantly higher in patients with steatosis (p = 0.034; p = 0.021; p = 0.023, respectively). CD34, CD34pt and CD34lfs differed significantly between patients with various steatosis grade (p = 0.006; p = 0.009; p = 0.013, respectively). CD34 and CD34pt differed significantly between each steatosis grade whereas CD34lfs between grade 1 and 3. Fibrosis stage and inflammatory grade were positively associated with steatosis extent (p = 0.015; p = 0.003, respectively). Our observations suggest that extensive steatosis of liver parenchyma in CHC patients is associated with formation of new blood vessels in lobules and portal tracts. Understanding the relationship between steatosis, fibrosis and angiogenesis is therefore of great importance for the introduction of new therapeutic approaches and in the evaluation of CHC progression.


  • Angiogenesis in chronic hepatitis C is associated with inflammatory activity grade and fibrosis stage

    by Andrzej Gabriel, Michał Kukla, Mariusz Wilk, Łukasz Liszka, Michał Petelenz, Joanna Musialik


  • 399 STEATOSIS INDUCES ANGIOGENESIS IN CHRONIC HEPATITIS C

    by M. Kukla, A. Gabriel, M. Wilk, L. Liszka, M. Petelenz, I. Frelich


  • Sole Use of Dexmedetomidine Has Limited Utility for Conscious Sedation during Outpatient Colonoscopy

    by Przemyslaw Jalowiecki, Robert Rudner, Maciej Gonciarz, Piotr Kawecki, Michal Petelenz, Piotr Dziurdzik

    Background: This study evaluated the ability of dexmedetomidine to provide analgesia and sedation for outpatient colonoscopy, examining outcomes including cardiorespiratory variables, side effects, and discharge readiness. Methods: Sixty-four patients were randomly assigned to one of three treatment regimens. In group D, patients received 1 microg/kg dexmedetomidine over 15 min followed by an infusion of 0.2 microg x kg x h. Group P received meperidine (1 mg/kg) with midazolam (0.05 mg/kg), and group F received fentanyl (0.1-0.2 mg intravenous) on demand. The assessment included measurements of heart rate, blood pressure, oxygen saturation, respiratory rate, quality of sedation/analgesia, and an evaluation of the recovery time. Results: The study was terminated before the planned 90 patients had been recruited because of adverse events in group D. In all groups, negligible hemoglobin oxygen saturation and respiratory rate variations were observed. In group D, there was a significantly larger decrease in heart rate (to approximately 40 beats/min in 2 of 19 cases) and blood pressure (to less than 50% of the initial value in 4 of 19 patients). Supplemental fentanyl was required in 47% of patients receiving dexmedetomidine to achieve a satisfactory level of analgesia (vs. 42.8% of patients in group P and 79.2% of patients in group F). Vertigo (5 patients), nausea/vomiting (5 patients), and ventricular bigeminy (1 patient) were observed only in group D. Time to home readiness was longest in group D (85 +/- 74, 39 +/- 21, and 32 +/- 13 min in groups D, P and F, respectively; P = 0.007). Conclusions: The use of dexmedetomidine to provide analgesia/sedation for colonoscopy is limited by distressing side effects, pronounced hemodynamic instability, prolonged recovery, and a complicated administration regimen.


  • Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: Preliminary results after one year

    by Joanna Musialik, Michal Petelenz, Zbigniew Gonciarz

    (2005). Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: Preliminary results after one year. Scandinavian Journal of Gastroenterology: Vol. 40, No. 7, pp. 873-874.


  • Sympathovagal Balance Fluctuates During Colonoscopy

    by M. Petelenz, M. Gonciarz, P. Macfarlane, R. Rudner, P. Kawecki, J. Musialik, P. Jalowiecki, Z. Gonciarz

    Background and Study Aim: Colonoscopy is a common gastroenterological procedure for investigation of the bowel. The main side effects of colonoscopy are pain during investigation, cardiovascular complications and very rarely even death. The aim of this study was to compare the continuous fluctuation of heart rate variability (HRV) components during colonoscopy under normal conditions, analgesia/sedation, and total intravenous anesthesia. Patients and Methods: 37 consecutive patients (aged 35 - 65), were randomly allocated to three groups: no sedation (control group 1); analgesia/sedation (group 2); and total intravenous anesthesia (group 3). Holter electrocardiography and subsequent frequency domain analysis were undertaken. The low-frequency (LF, 0.04 - 0.15Hz) and the high-frequency (HF, 0.15 - 0.40Hz) components were estimated using spectral analysis in the usual way. Normalized units (nu) were calculated from the following equations: LFnu = LF/(LF + HF), and HFnu = HF/(LF + HF). Results: Groups 2 and 3 were found to have a significantly lower HFnu and higher LFnu than group 1 essentially throughout the procedure. A one-way analysis of variance and t-test confirmed that the differences were significant when the colonoscope reached the splenic flexure as were the LF/HF balances at the splenic and hepatic flexures and the cecum. The percentage change in LF/HF was also analyzed, and it was found that in group 3 the mean change was over 136 % when the colonoscope reached the sigmoid flexure, which was significantly higher than in the other two groups. Conclusion: Most changes in HRV components occurred during colonoscopy of the left side of the bowel. Analgesia/sedation and total intravenous anesthesia increased HRV by increasing the LF component.